









Markets
/
Stocks
/
nasdaq-rapt
/

RAPT Therapeutics Inc

RAPT



View Detailed Chart

35.420USD

-0.420-1.17%

Close 12/26, 16:00（ET）Quotes delayed by 15 min

597.02MMarket Cap

LossP/E TTM



RAPT Therapeutics Inc

35.420

-0.420-1.17%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.17%

5 Days

+4.76%

1 Month

+6.49%

6 Months

+320.17%

Year to Date

+180.22%

1 Year

+161.98%

View Detailed Chart

TradingKey Stock Score of RAPT Therapeutics Inc

Currency: USD Updated: 2025-12-26

Key Insights

RAPT Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 111/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 58.22.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

RAPT Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

111 / 404

Overall Ranking

228 / 4563

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

58.222

Target Price

+66.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

RAPT Therapeutics Inc Highlights

StrengthsRisks

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -3.04, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 16.78M shares, decreasing 6.82% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 696.19K shares of this stock.